FDA Approves 23andMe Consumer Test for Hereditary CRC Syndrome

January 23, 2019 – The FDA has cleared a direct-to-consumer genetic test for a risk report on MUTYH-associated polyposis, a hereditary colorectal cancer (CRC) syndrome, announced 23andMe, the personal genetics company that manufactures the test. The approval will allow the company to report on the 2 most common genetic variants that influence MUTYH-associated polyposis. Upon its release, the test will be offered to new and existing customers of … (leggi tutto)